Regulus Therapeutics Inc (Nasdaq:RGLS) stated on Friday that Timothy Wright has stepped down as its chief research and development officer with immediate effect.
Dr Wright has submitted his resignation to the company for personal reasons to pursue a new opportunity.
However, Dr Wright will continue to support the company as its scientific advisor, will enable a smooth transition as well as support its interactions with us FDA regarding RGLS4326, a novel oligonucleotide designed to inhibit miR-17 and designed to preferentially target the kidney.
With corporate headquarters in La Jolla, CA, the biopharmaceutical company is focused on the discovery and development of innovative medicines targeting microRNAs.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval